Articles By Peter Nash
TRBV9+ a novel treatment approach for AxSpA?
By Peter Nash
HLA-B27 is the strongest genetic risk factor for AxSpA positive in 90% of rAxSpA and 30-40% of PsA patients. B27 is an MHC class1 molecule which presents peptide to CD8 T cells. Current therapies treat inflammation but do not eliminate the cellular drivers of disease and only 40-60% of AxSpA patients achieve adequate disease control. Further, only 45% of PsA patients achieve minimal disease activity.
Read Article